Accent Therapeutics is a biotechnology company focused on developing small molecule precision cancer therapies that target critical intracellular dependencies across various types of cancer. They leverage their expertise in RNA-modifying protein (RMP) biology to identify and exploit intracellular dependencies and develop therapeutics with far-reaching potential. Accent Therapeutics primarily serves the healthcare industry.

Accent Therapeutics

Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.

Atlas Venture

EcoR1 Capital

The Column Group

The Mark Foundation for Cancer Research

AbbVie Biotech Ventures

Google Ventures

Droia Ventures

NS Investment

Accent Therapeutics, Inc. 

Excited to be sharing Accent’s pipeline progress at this year’s Triple Meeting! Maureen Lynes, Jennifer Castro, Gordon J Lockbaum, Shane Buker

https://lnkd.in/eigv_Px9

Congratulations Katalin Karikó and Drew Weissman for receiving The Nobel Prize for Medicine for your mRNA discoveries, which have led to powerful new medicines for patients! At Accent, we share this excitement for advancing the field of mRNA biology to serve patients in need.  https://lnkd.in/dUFuYQW7 

Welcome Jason Sager, Stuart Ince, and Steven Mennen!  Accent is excited to build our capabilities to bring our first two programs into the clinic! 

https://lnkd.in/evbQkmpP

An important part of early drug discovery efforts is the development of the assay toolkit that will be used to identify, validate and characterize hit compounds that can be optimized into therapeutic molecules. In Gotur et al, SLAS Discovery, 2023 (https://lnkd.in/eXPEAJGF), Accent discloses the suite of biochemical, biophysical and structural tools for DHX9 and demonstrates their utility in identifying a nucleotide analog inhibitor of the enzyme. In addition to furthering investigations into DHX9 biology, this publication also provides a framework for the development of assays for other helicases of biological interest.

COM:ACCENTTX

Accent Therapeutics